Marshall Wace, LLP Satsuma Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

  • $72.2 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$4.19 - $7.95 $42,415 - $80,477
10,123 New
10,123 $61,000
Q2 2021

Aug 13, 2021
SELL
$4.8 - $7.25 $45,796 - $69,172
-9,541 Reduced 11.96%
70,247 $495,000
Q1 2021

May 17, 2021
BUY
$4.57 - $7.18 $364,631 - $572,877
79,788 New
79,788 $472,000

About Satsuma Pharmaceuticals, Inc.

STSA Quotes by TradingView
  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email